Cargando…

Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway

Aim. This study aimed to investigate whether the glucagon-like peptide-1 analog liraglutide (LIRA) can protect against diabetic cardiomyopathy and explore the related mechanism. Methods. Rats were divided into 6 groups: a nondiabetic group, diabetic cardiomyopathy rats without LIRA treatment, diabet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jieyu, Liu, Yu, Chen, Li, Wang, Yuehui, Li, Junqi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647568/ https://www.ncbi.nlm.nih.gov/pubmed/23671882 http://dx.doi.org/10.1155/2013/630537

Ejemplares similares

Glucagon-Like Peptide-1 Analog, Liraglutide, Delays Onset of Experimental Autoimmune Encephalitis in Lewis Rats
por: DellaValle, Brian, et al.
Publicado: (2016)

Glucagon-like peptide-1 analog liraglutide leads to multiple metabolic alterations in diet-induced obese mice
por: Park, Seokjae, et al.
Publicado: (2022)

A glucagon-like peptide-1 analog, liraglutide, ameliorates endothelial dysfunction through miRNAs to inhibit apoptosis in rats
por: Zhang, Qian, et al.
Publicado: (2019)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
por: Sawada, Noritaka, et al.
Publicado: (2020)

Chronic Administration of the Glucagon-Like Peptide-1 Analog, Liraglutide, Delays the Onset of Diabetes and Lowers Triglycerides in UCD-T2DM Rats
por: Cummings, Bethany P., et al.
Publicado: (2010)

The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes
por: Shimoda, M., et al.
Publicado: (2011)

Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism
por: Krasner, Nadia M., et al.
Publicado: (2014)

The once‐daily human glucagon‐like peptide‐1 analog, liraglutide, improves β‐cell function in Japanese patients with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2012)

Exercise protects against diabetic cardiomyopathy by the inhibition of the endoplasmic reticulum stress pathway in rats
por: Chengji, Wang, et al.
Publicado: (2018)

Effect of liraglutide on endoplasmic reticulum stress in the renal tissue of type 2 diabetic rats
por: Zhao, Xuan-Ye, et al.
Publicado: (2020)

The glucagon‐like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents
por: Vallöf, Daniel, et al.
Publicado: (2015)

Protective effect of glucagon-like peptide-1 mediated by ultrasound microbubbles on myocardial injury in rats with diabetic cardiomyopathy
por: Liu, Yanjie, et al.
Publicado: (2022)

Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension
por: Helmstädter, Johanna, et al.
Publicado: (2020)

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
por: Zinman, Bernard, et al.
Publicado: (2009)

Glucagon-Like Peptide-1 Agonists Protect Pancreatic β-Cells From Lipotoxic Endoplasmic Reticulum Stress Through Upregulation of BiP and JunB
por: Cunha, Daniel A., et al.
Publicado: (2009)

Endoplasmic Reticulum Stress and Diabetic Cardiomyopathy
por: Xu, Jiancheng, et al.
Publicado: (2012)

Newer Vistas in Glucagon-Like Peptide-1 Analog Therapy - Marvels of Peptide Engineering
por: Jacob, Jubbin Jagan, et al.
Publicado: (2021)

Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes.
por: Lu, Nan, et al.
Publicado: (2015)

Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Jinnouchi, Hideaki, et al.
Publicado: (2015)

Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits
por: Ebdrup, Bjørn H, et al.
Publicado: (2012)

Bolus Injection of Liraglutide Raises Plasma Glucose in Normal Rats by Activating Glucagon-like Peptide 1 Receptor in the Brain
por: Hsu, Chia-Chen, et al.
Publicado: (2022)

Endoplasmic Reticulum Stress-Related Factors Protect against Diabetic Retinopathy
por: Hu, Wei-Kun, et al.
Publicado: (2012)

Liraglutide Activates Glucagon-Like Peptide 1 Receptor to Attenuate Hyperglycemia through Endogenous Beta-Endorphin in Diabetic Rats
por: Cheng, Kai-Chun, et al.
Publicado: (2020)

Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
por: Yazıcı, Dilek, et al.
Publicado: (2022)

The Global Transcriptional Response of Isolated Human Islets of Langerhans to Glucagon-Like Peptide-1 Receptor Agonist Liraglutide
por: Zhao, Xiaoning, et al.
Publicado: (2012)

Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor–Expressing Glutamatergic Neurons
por: Adams, Jessica M., et al.
Publicado: (2018)

The impact of the glucagon‐like peptide 1 receptor agonist liraglutide on the streptozotocin‐induced diabetic mouse kidney proteome
por: Liljedahl, Leena, et al.
Publicado: (2019)

Effects of insulin and the glucagon‐like peptide 1 receptor agonist liraglutide on the kidney proteome in db/db mice
por: Liljedahl, Leena, et al.
Publicado: (2017)

Fifty‐two‐week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon‐like peptide‐1 analog liraglutide vs glibenclamide in patients with type 2 diabetes
por: Kaku, Kohei, et al.
Publicado: (2011)

Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide
por: Schiavon, Michele, et al.
Publicado: (2021)

Glucagon-like peptide-1 receptor regulates endoplasmic reticulum stress-induced apoptosis and the associated inflammatory response in chondrocytes and the progression of osteoarthritis in rat
por: Chen, Jian, et al.
Publicado: (2018)

Glucagon-Like Peptide-1 Receptor Agonist Protects Against Diabetic Cardiomyopathy by Modulating microRNA-29b-3p/SLMAP
por: Fang, Ping, et al.
Publicado: (2023)

Protective potential of glucagon like peptide 2 (GLP-2) against the neurodegeneration
por: Amato, Antonella, et al.
Publicado: (2019)

Glucagon-like peptide-1 receptor activation stimulates PKA-mediated phosphorylation of Raptor and this contributes to the weight loss effect of liraglutide
por: Le, Thao DV, et al.
Publicado: (2023)

Mitochondria-Endoplasmic Reticulum Contacts: The Promising Regulators in Diabetic Cardiomyopathy
por: Chen, Yan, et al.
Publicado: (2022)

Glucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malaria
por: DellaValle, Brian, et al.
Publicado: (2016)

Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats
por: Inoue, Kazuho, et al.
Publicado: (2022)

The Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Stimulates Mechanistic Target of Rapamycin (mTOR) Signaling via PKA And Akt
por: Le, Thao D V, et al.
Publicado: (2021)

Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus
por: Bretón‐Romero, Rosa, et al.
Publicado: (2018)

Endoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosine
por: Bonilla, Ximena, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gd716j70om261uqn4a7k2edvpu